'Limited treatment duration and re-induction with the same regimen on progression' vs 'treatment until progression' with biweekly capecitabine + oxaliplatin +/- bevacizumab in patients (PTS) with advanced colorectal cancer (CLC): a randomised phase II study

Trial Profile

'Limited treatment duration and re-induction with the same regimen on progression' vs 'treatment until progression' with biweekly capecitabine + oxaliplatin +/- bevacizumab in patients (PTS) with advanced colorectal cancer (CLC): a randomised phase II study

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Jun 2009

At a glance

  • Drugs Bevacizumab (Primary) ; Capecitabine; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Jun 2009 Results were reported at the 11th World Congress on Gastrointestinal Cancer.
    • 10 Oct 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top